Key Points
• Conclusion/Relevance: “Epstein-Barr virus positive B-cell lymphoproliferative disorder (EBV+ B-LPD) encompasses a broad clinicopathological spectrum and distinct clinical behavior that relatively favors the gastrointestinal (GI) tract. In this review, we provide an update on the clinicopathological features and biological behavior of EBV-positive mucocutaneous ulcer (EBVMCU) and primary EBV+ diffuse large B-cell lymphoma (DLBCL) of the GI tract.”
• Although EBVMCU is novel, it is widely recognized as an indolent and self-limited EBV+ B-cell lymphoproliferative disorder (B-LPD) present in a number of immunodeficiencies. EBV+ DLBCL, however, is the largest constituent of EBV+ B-LPDs and is thought to be aggressive neoplasm.
• “EBV+ giDLBCL presents an aggressive clinical course, but EBV+ gDLBCL cases with a single lesion in Lugano stage I have extremely favorable outcomes, which may indicate that this subgroup is distinctive and possibly classifiable as EBVMCU,” the authors concluded.
• The authors noted that unlike giEBVMCU, EBV+ giDLBCL is strongly correlated with PD-L1 expression on tumor cells or immune cells, which could help with diagnosis, as well as proving useful in evaluating either immune escape or immunodeficiency in the pathogenesis of EBV+ B-LPDs.